Abraxis: Emergent Life Science & Pharmaceutical Company Abraxis BioScience, Inc. Michael J. Brunelle, VP Acquisition & Development UGL Equis Mark Berman, Managing Director Brad Gross, Senior Vice President
Table of Contents Los Angeles Market Overview Overview of Abraxis BioScience Abraxis BioScience The Biotech Innovator The Abraxis/ UGL Equis Relationship Overview of Services & Transactions Services Provided Transactions Completed Over Past Two Years The Future Other West Los Angeles Office Case Studies 2
Los Angeles Market Overview Submarket Breakdown Inventory Analysis Vacancy Rates Historical Rental Rates Sales Activity Analysis 2008 Forecast 3
Los Angeles Market Overview Submarket Breakdown together with Leasing & Vacancy Highlights 4
Los Angeles Market Overview Inventory Analysis 5
Los Angeles Market Overview Vacancy Rates 6
Los Angeles Market Overview Historical Rental Rates 7
Los Angeles Market Overview Sales Activity Analysis 8
Overview of Abraxis BioScience Abraxis BioScience is a fully integrated global biotechnology company dedicated to delivering progressive therapeutics, such as ABRAXANE, and core technologies that have the potential to offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. 9
Overview of Abraxis BioScience The Biotech Innovator Headquarters: Los Angeles, CA with 500 employees Internally discovered, developed & launched in USA and Canada the first proteinbound paclitaxel formulation: ABRAXANE Fastest growing taxane in metastatic breast cancer within 2 years of launch with >100 Phase 2 studies January 22, 2008 - Abraxis Bioscience receives approval from EU Commission to market ABRAXANE for mbc in Europe. Imminent approval of ABRAXANE in China with ongoing development in Japan and ROW Owns nab platform technology with four drugs entering clinical trials Fully integrated infrastructure for drug discovery, clinical development, regulatory filing, protein-bound particle manufacture and commercial launch 2007 revenue $285M, with over $700M cash on hand 10
The Abraxis/UGL Relationship Proven Track Record of Success Collaborative Working Relationship Forward Thinking Advisory, Resulting in Strategy Driven Plans Transforming Real Estate into a Competitive Advantage Consistent Delivery and Integration of Multitude of Services Lines Client Focused Process that Delivers Results Accessible, Responsive, Dedicated, Smart, Creative, Responsible, Honest, Passionate, Client First Philosophy 11
Overview of Services & Transactions Services Provided Transaction Advisory Workplace Integration Facility Management Financial Analysis UGL Unicco Audit & Recovery (to be integrated) Data Management (to be Integrated) 12
Overview of Services & Transactions Transactions Completed Over Past Two Years Corporate Headquarters 11755 Wilshire Boulevard, Los Angeles, CA; 50,000 SF, Multiple Transactions Lease Transactions 4505 Emperor Boulevard, Durham, NC; 29,000 SF 4505 Emperor Boulevard, Durham, NC; 7,100 SF (Expansion) 4503 Glencoe Avenue, Marina del Rey, CA; 51,000 SF 200 Somerset Corporate Boulevard, Bridgewater, NJ; 33,000 SF 523 West Sixth Street, Los Angeles, CA; 4,500 SF 43 Corporate Park, Irvine, CA; 1,500 SF Sale Transactions 9920 W. Jefferson Boulevard, Culver City, CA; 60,000 SF 620 N. 51st Avenue, Phoenix, AZ; 110,000 SF (Consulting) International Lease Transactions London, UK; 3,500 SF 13
Overview of Services & Transactions The Future Paris, France Berlin, Germany Expansion of UK presence Expansion of Los Angeles Headquarters Data Management and Audit & Recovery 14
Other West Los Angeles Office Case Studies Los Angeles Unified School District (LAUSD) Motorcar Parts of America, Inc. California Portland Cement Company Robins, Kaplan, Miller & Ciresi LLP OSI Systems, Inc. Pandemic Studios 15
www.unitedgroupltd.com